BACE1 is also linked to pathophysiological processes, in particular to Alzheimer’s disease where it is a major drug target because it cleaves the amyloid precursor protein (APP) and catalyzes the first step in the generation of the amyloid β peptide, a key pathogenic agent in Alzheimer’s disease [3]. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.